New drug combo aims to wipe out prostate cancer before surgery
NCT ID NCT06834321
Summary
This study is testing whether adding a drug called homoharringtonine to standard hormone therapy before prostate cancer surgery can better shrink or eliminate tumors. It will involve 96 men with locally advanced or limited metastatic prostate cancer. The goal is to see if this combination leads to fewer cancer cells remaining after surgery compared to hormone therapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First People Hospital of Nantong City
RECRUITINGNantong, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhongda Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.